PHILADELPHIA, July 17, 2012 /PRNewswire/ — ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations (CROs), today announced it has received two additional patents from the United States Patent and Trademark Office (U.S. Patent No. 8,065,180 and U.S. Patent No. 8,145,519). The patents are titled System for Clinical Trial Subject Compliance and were acquired by ERT as part of the recent acquisition of invivodata.
“We are very pleased to be issued these additional patents,” said Saul Shiffman, Ph.D., pioneer of the electronic patient reported outcomes industry, invivodata founder and one of the inventors of this intellectual property. “It is extremely rewarding to have our processes, which are based on proven scientific principles, be recognized in this manner and to see first-hand the benefits they are delivering to researchers who seek the most reliable and valid patient-centered data possible.”
The patents announced today cover the tracking and enhancement of participant compliance with a research protocol and can also be used to provide evaluability data related to participant performance in a clinical trial. Participant compliance is defined as the degree to which trial participants (patients and study team – including investigative site personnel) meet the expectations of the trial sponsor with regard to using a diary or other reporting mechanism torecord answers to questions about their experiences during the trial.
Participant compliance with the research protocol is critical to ensuring the success of clinical trials. ERT’s electronic diary solutions – DIARYpro® for remote patient data collection, and SITEpro® (for site-based data collection) – are built on these patented compliance-enhancing methods and have been repeatedly proven to capture important COA data at the point of the participant’s experience, yielding a more accurate measurement of treatment effect.
ERT has launched a tiered licensing program to enable other industry suppliers to include this innovative functionality in their products. Initial contacts have already been made with the key eDiary providers and several have expressed interest in participating. “We will support an open dialogue with other eDiary providers that may want to include participant compliance enhancing features in their solutions,” said Dr. Jeffrey Litwin, CEO of ERT. “This constructive dialogue is essential to ensure that the drug-development community has access to the best possible research tools, while protecting our innovative and valuable intellectual property.”
ERT leads the industry in creating and deploying meaningful innovations that advance the collection of effective COA data for clinical research. A sample of these innovations and industry-firsts include: creation of the first handheld patient eDiary, first wireless eDiary solution, first scientific demonstration of significant increases in patient compliance with eDiaries, first new drug approved based on primary efficacy data collected on an eDiary, and the first proven increase in study power due to the integrity of eDiary data.
For information on these and other innovations, as well as ERT’s solutions and services for COA data collection, cardiac safety, and respiratory efficacy services please visit www.ert.com.
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with reliable processes and scientific expertise to collect, analyze, and report on clinical data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety, respiratory efficacy services, and Clinical Outcome Assessment (COA) solutions, including electronic patient, clinician, and observer reported outcomes.
Tel: +44 7703 532 749